Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 20075214)

1.

Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.

Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S.

Science. 2010 Feb 5;327(5966):697-701. doi: 10.1126/science.1180556. Epub 2010 Jan 14.

2.

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

Blower SM, Gershengorn HB, Grant RM.

Science. 2000 Jan 28;287(5453):650-4.

3.

Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.

Goudsmit J, Weverling GJ, van der Hoek L, de Ronde A, Miedema F, Coutinho RA, Lange JM, Boerlijst MC.

AIDS. 2001 Nov 23;15(17):2293-301.

PMID:
11698703
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

Adjé C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respess R, Wiktor SZ, Chorba T, Nkengasong JN; UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):501-6.

PMID:
11391173
6.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
7.

Emergence of antiretroviral drug resistance in therapy-naive HIV infected patients in Hungary.

Juhász E, Ghidán A, Kemény B, Nagy K.

Acta Microbiol Immunol Hung. 2008 Dec;55(4):383-94. doi: 10.1556/AMicr.55.2008.4.3.

PMID:
19130746
8.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, Harrigan PR.

J Infect Dis. 2004 Jul 15;190(2):285-92. Epub 2004 Jun 11.

9.

Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing.

Birch C, Middleton T, Hales G, Cooper D, Law M, Crowe S, Hoy J, Emery S.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):57-61.

PMID:
12514414
10.

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

Montaner JS, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, Yip B, Harris M, Montessori V, O'Shaughnessy MV.

AIDS. 2001 Jan 5;15(1):61-9.

PMID:
11192869
11.

Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.

Blower S, Ma L, Farmer P, Koenig S.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):345-53. Review.

PMID:
14754434
12.

Salvage therapy for patients failing their current antiretroviral regimen.

Albrecht MA.

AIDS Clin Rev. 2000-2001:139-91. Review. No abstract available.

PMID:
10999220
13.

[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].

Gutiérrez F, Moltó J, Escolano C, Mora A, Pasquau F, Gregori J, Nogueira E.

Med Clin (Barc). 2000 Oct 7;115(11):401-4. Spanish.

PMID:
11093841
14.

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.

Masquelier B, Costagliola D, Schmuck A, Cottalorda J, Schneider V, Izopet J, Calvez V, Descamps D, Poggi C, Brun-Vézinet F; ANRS resistance sudy group.

J Med Virol. 2005 Aug;76(4):441-6.

PMID:
15977249
15.

Predicting the unpredictable: transmission of drug-resistant HIV.

Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO.

Nat Med. 2001 Sep;7(9):1016-20. Erratum in: Nat Med. 2003 Jan;9(1):146..

PMID:
11533704
16.

The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.

Zhang M, Han XX, Cui WG, Jia MH, Meng XD, Xing AH, Wu YH, Yang YY, Lu CM, Hu QH, Dai D, Zhang ZN, Shang H.

Jpn J Infect Dis. 2008 Sep;61(5):361-5.

17.

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.

Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M.

AIDS. 2002 Jul 26;16(11):1511-9.

PMID:
12131189
18.

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.

Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, Leal M, Soriano V; ERASE-3 Group.

AIDS. 2001 Sep 28;15(14):1894-6.

PMID:
11579258
19.

Reversibility of HIV drug resistance.

Davenport MP.

Science. 2000 May 26;288(5470):1299. No abstract available.

20.

Antiretroviral therapy and resistance to antiretroviral drugs.

Lange JM, van Leeuwen R.

Ethiop Med J. 2002 Apr;40 Suppl 1:51-75. Review.

PMID:
12802831
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk